The evolving SARS-CoV-2 epidemic in Africa: Insights from rapidly expanding genomic surveillance

Competing Interest Statement

With the exception of Pardis Sabeti who is a co-founder of and consultant to Sherlock Biosciences and a Board Member of Danaher Corporation and who holds equity in the companies, we the authors have no conflicts of interest to declare.

Funding Statement

Sequencing efforts in the African Union Member States were supported by the Africa Center for Disease Control (Africa CDC) - Africa Pathogen Genomics Initiative (Africa PGI), and the World Health Organization Regional Office for Africa (WHO AFRO) through the transfer of laboratory infrastructure, the provision of reagents and training. The Africa PGI is supported by the African Union, Centers for Disease Control and Prevention (CDC), Bill and Melinda Gates Foundation (BMGF), Illumina Inc, Oxford Nanopore Technologies (ONT) and other partners. In addition, all Institut Pasteur organizations and CERMES in Niger are part of the PEPAIR COVID-19-Afirica project which is funded by the French Ministry for European and Foreign Affairs. KRISP and CERI is furthermore supported in part by grants from the World Health Organization, the Abbott Pandemic Defense Coalition (APDC), the National Institute of Health USA (U01 AI151698) for the United World Antivirus Research Network (UWARN) and the INFORM Africa project through IHVN (U54 TW012041), H3BioNet Africa (Grant # 2020 HTH 062), the South African Department of Science and Innovation (SA DSI) and the South African Medical Research Council (SAMRC) under the BRICS JAF #2020/049. ILRI is also supported by the Ministry for Economic Cooperation and Federal Development of Germany (BMZ). Work conducted at ACEGID is made possible by support provided to ACEGID by a cohort of generous donors through TED's Audacious Project, including the ELMA Foundation, MacKenzie Scott, the Skoll Foundation, and Open Philanthropy. Work at ACEGID was also partly supported by grants from the National Institute of Allergy and Infectious Diseases (https://www.niaid.nih.gov), NIH-H3Africa (https://h3africa.org) (U01HG007480 and U54HG007480), the World Bank (projects ACE-019 and ACE-IMPACT), the Rockefeller Foundation (Grant #2021 HTH), the Africa CDC through the African Society of Laboratory Medicine [ASLM] (Grant #INV018978), the Wellcome Trust (Project 216619/Z/19/Z) and the Science for Africa Foundation. Sequencing efforts at the National Institute for Communicable Diseases (NICD) was also supported by a conditional grant from the South African National Department of Health as part of the emergency COVID-19 response; a cooperative agreement between the National Institute for Communicable Diseases of the National Health Laboratory Service and the United States Centers for Disease Control and Prevention (FAIN# U01IP001048; NU51IP000930); the South African Medical Research Council (SAMRC, project number 96838); the African Society of Laboratory Medicine (ASLM) and the Bill and Melinda Gates Foundation grant number INV-018978; the UK Foreign, Commonwealth and Development Office and Wellcome (Grant no 221003/Z/20/Z); and the UK Department of Health and Social Care and managed by the Fleming Fund and performed under the auspices of the SEQAFRICA project. Funding for sequencing efforts in Angola was supported through Projecto Bongola (N. 11/MESCTI/PDCT/2020) and OGE INIS (2020/2021). Botswana's sequencing efforts led by the Botswana Harvard AIDS Institute Partnership was supported by: Foundation for Innovative New Diagnostics(FINDdx); Bill and Melinda Gates Foundation, H3ABioNet [U41HG006941], Sub-Saharan African Network for TB/HIV Research Excellence (SANTHE) and Fogarty International Center (Grant # 5D43TW009610) . H3ABioNet is an initiative of the Human Health and Heredity in Africa Consortium (H3Africa) programme of the African Academy of Science (AAS). HHS/NIH/National Institute of Allergy and Infectious Diseases (NIAID) (5K24AI131928-04; 5K24AI131924-04); SANTHE is a DELTAS Africa Initiative [grant # DEL-15-006]. The DELTAS Africa Initiative is an independent funding scheme of the African Academy of Sciences (AAS)'s Alliance for Accelerating Excellence in Science in Africa (AESA) and supported by the New Partnership for Africa's Development Planning and Coordinating Agency (NEPADAgency) with funding from the Wellcome Trust [grant #107752/Z/15/Z] and the United Kingdom (UK) government. From Brazil, Joicymara Santos Xavier was funded by Coordena'ao de Aperfei'oamento de Pessoal de Nivel Superior - Brazil (CAPES) - Finance Code 001. Sequencing efforts from Cote d'Ivoire were funded by the Robert Koch Institute and the German Federal Ministry of Education and Research (BMBF). Sequencing efforts in the Democratic Republic of the Congo were funded by the Bill & Melinda Gates Foundation under grant INV-018030 awarded to CBP and further supported by funding from the Africa CDC through the ASLM (African Society of Laboratory Medicine) for Accelerating SARS-CoV-2 Genomic Surveillance in Africa, the US Centre for Disease Control and Prevention (US CDC), USAMRIID, IRD/Montepellier, UCLA and SACIDS FIND. Efforts from Egypt was funded by the Egyptian Ministry of Health (REF#), the Egyptian Academy for Scientific Research and Technology (ASRT) JESOR project #3046 (Center for Genome and Microbiome Research), the Cairo University anti COVID-19 fund and the Science and Technology Development Fund (STDF), Project ID: 41907. The sequencing effort in Equatorial Guinea was supported by a public-private partnership, the Bioko Island Malaria Elimination Project, composed of the government of Equatorial Guinea Ministries of Mines and Hydrocarbons, and Health and Social Welfare, Marathon EG Production Limited, Noble Energy, Atlantic Methanol Production Company, and EG LNG. Analysis for the Gabon strains was supported by the Science and Technology Research Partnership for Sustainable Development (SATREPS), Japan International Cooperation Agency (JICA), and Japan Agency for Medical Research and Development (AMED) (grant number JP21jm0110013) and a grant from AMED (grant number JP21wm0225003). CIRMF (Gabon) is funded by the Gabonese Government and TOTAL Energy inc. CIRMF is a member of CANTAM supported by EDCTP. The work at WACCBIP (Ghana) was funded by a grant from the Rockefeller Foundation (2021 HTH 006), an Institut de Recherche pour le Developpement (IRD) grant (ARIACOV), African Research Universities Alliance (ARUA) Vaccine Development Hubs grant with funds from Open Society Foundation, National Institute of Health Research (NIHR) (17.63.91) grants using UK aid from the UK Government for a global health research group for Genomic surveillance of malaria in West Africa (Wellcome Sanger Institute, UK) and the World Bank African Centres of Excellence Impact grant (WACCBIP-NCDs: Awandare). In addition to the funding sources from ILRI, KEMRI (Kenyan) contributions to sequencing efforts was supported in part by the National Institute for Health Research (NIHR) (project references 17/63/82 and 16/136/33) using UK aid from the UK Government to support global health research, and The UK Foreign, Commonwealth and Development Office (FCDO) and Wellcome (grant# 220985/Z/20/Z) and the Kenya Medical Research Institute Grant # KEMRI/COV/SPE/012. Contributions from Lesotho was supported by the Africa CDC, African Society for Laboratory Medicine (ALSM) and the South African National Institute for Communicable Diseases (SA NICD). Liberian efforts was funded by the Africa CDC through a subaward from the Bill and Melinda Gates Foundations (REF#), while efforts from Madagascar were funded by the French Ministry for Europe and Foreign Affairs through the REPAIR COVID-19-Africa project coordinated by the Pasteur International Network association. Sequencing from Malawi was supported by Wellcome Trust (REF#). Contributions from Mali was supported by Fogarty International Center and National Institute of Allergy and Infectious Diseases sections of the National Institutes of Health under Leidos-15X051, award numbers U2RTW010673 for the West African Center of Excellence for Global Health Bioinformatics Research Training and U19AI089696 and U19AI129387 for the West Africa International Center of Excellence for Malaria Research. Sequencing efforts from Morocco have been supported by Academie Hassan II of Science and Technology, Morocco. Funding for surveillance, sampling and testing in Madagascar: World Health Organization (WHO), the US Centers for Disease Control and Prevention (US CDC: Grant#U5/IP000812-05), the United States Agency for International Development (USAID: Cooperation Agreement 72068719CA00001), the Office of the Assistant Secretary for Preparedness and Response in the U.S. Department of Health and Human Services (DHHS: grant number IDSEP190051-01-0200). Funding for sequencing: Bill & Melinda Gates Foundation (GCE/ID OPP1211841), Chan Zuckerberg Biohub, and the Innovative Genomics Institute at UC Berkeley. Mozambique acknowledges support from the Mozambican Ministry of Health and the Bill and Melinda Gates Foundation (REF#). Namibian efforts was supported by Africa CDC through a subaward from the Bill and Melinda Gates Foundations (REF#). Efforts from the country Niger were supported by the French Ministry for Europe and Foreign Affairs through the REPAIR COVID-19-Africa project coordinated by the Pasteur International Network association. In addition to the funding support for ACEGID already listed, Nigeria's contributions were made possible by support from Flu Lab and a cohort of generous donors through TED's Audacious Project, including the ELMA Foundation, MacKenzie Scott, the Skoll Foundation, and Open Philanthropy. Efforts from the Republic of the Congo was supported by the European and Developing Countries Clinical Trials Partnership (EDCTP) IDs: PANDORA, CANTAM and German Academic Exchange Service (DAAD) IDs: PACE-UP; DAAD Project ID: 5759234. Rwanda's contributions were made possible by funding from the African Network for improved Diagnostics, Epidemiology and Management of common Infectious Agents (ANDEMIA) was granted by the German Federal Ministry of Education and Research (BMBF grant 01KA1606, 01KA2021 and 01KA2110B) and the National Institute of Health Research (NIHR) Global Health Research programme (16/136/33) using UK aid from the UK Government. In addition to the South African institutions listed above, the University of Cape Town's work was supported by the Wellcome Trust [Grant # 203135/Z/16/Z], EDCTP RADIATES (RIA2020EF-3030), the South African Department of Science and Innovation (SA DSI) and the South African Medical Research Council (SAMRC), Stellenbosch University's contributions by the South African Medical Research Council (SA-MRC), and the University of Pretoria's contributions funded by the G7 Global Health Fund (REF#) and the BMBF ANDEMIA grant (REF#). Funding from the Fleming Fund (REF#) supported sequencing in Sudan. The Ministry of Higher Education and Scientific Research of Tunisia provided funding for sequencing from Tunisia. UVRI (Uganda) acknowledge support from the Wellcome Trust and FCDO - Wellcome Epidemic Preparedness - Coronavirus (AFRICO19, grant agreement number 220977/Z/20/Z), from the MRC (MC_UU_1201412) and from the UK Medical Research Council (MRC/UKRI) and FCDO (DIASEQCO, grant agreement number NC_PC_19060). Research at the FredHutch institute which supported bioinformatics analyses of sequences in the present study was supported by the Bill and Melinda Gates foundation (#INV-018979). Research support from Broad Institute colleagues was made possible by support from Flu lab and a cohort of generous donors through TED's Audacious Project, including the ELMA Foundation, MacKenzie Scott, the Skoll Foundation, Open Philanthropy, the Howard Hughes Medical Institute and NIH (U01AI151812 and U54HG007480) (P.C.S.). Work from Quadram Institute Bioscience was funded by The Biotechnology and Biological Sciences Research Council Institute Strategic Programme Microbes in the Food Chain BB/R012504/1 and its constituent projects BBS/E/F/000PR10348, BBS/E/F/000PR10349, BBS/E/F/000PR10351, and BBS/E/F/000PR10352 and by the Quadram Institute Bioscience BBSRC funded Core Capability Grant (project number BB/CCG1860/1). Sequences generated in Zambia through PATH were funded by the Bill & Melinda Gates Foundation and Africa CDC (REF#). The content and findings reported herein are the sole deduction, view and responsibility of the researcher/s and do not reflect the official position and sentiments of the funding agencies.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The African samples processed in this study were obtained anonymously from material exceeding the routine diagnosis of SARS- CoV-2 in African public and private health laboratories. Individual institutional review board (IRB) references or material transfer agreements (MTAs) for countries are listed in the PDF under Material and Methods: Ethics statement.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes